Our Leadership Team has a broad range of experience and is responsible for managing the business on a day‑to‑day basis.
Dame Louise Makin
Chief Executive Officer
Dame Louise Makin, MA, PhD (Cantab), MBA, DBE, joined BTG as Chief Executive Officer in October 2004. She is a non-executive director of Intertek Group plc and the Woodford Patient Capital Trust, a Trustee of the Outward Bound Trust, Chair of the 1851 Trust, an Honorary Fellow of St. John’s College, Cambridge and a member of the 30% Club.
From 2001, she was President, Biopharmaceuticals Europe of Baxter Healthcare, where she was responsible for Europe, Africa and the Middle East. Louise joined Baxter Healthcare in 2000 as Vice President, Strategy & Business Development Europe. Before joining Baxter, she was Director of Global Ceramics at English China Clay and prior to that she held a variety of roles at ICI between 1985 and 1998.
Chief Financial Officer
Duncan Kennedy joined BTG in December 2005 as Group Financial Controller and in April 2012 he joined the Leadership Team as Group Director of Finance, with management responsibility for the global finance function. Duncan led BTG's Interventional Oncology business from May 2015 until he began as CFO in January 2018.
Prior to joining BTG, Duncan spent six years in the group finance function of Wembley plc, an international leisure group, gaining wide-ranging experience in all aspects of listed company financial reporting and significant involvement in corporate transactions. Duncan qualified as a Chartered Accountant at Arthur Andersen and holds a BSc in Mathematics from Durham University.
Chief Scientific Officer
Melanie Lee, PhD, CBE, FMedSci, DSc (Hons), became BTG’s Chief Scientific Officer in November 2014 having previously served as a non-Executive Director at the company since November 2010.
Melanie previously served as the Chief Executive Officer of NightstaRx Ltd, a Founder and Director of the pharmaceutical consultancy Think10, and a non-executive director of H Lundbeck A/S. Melanie was CEO of Syntaxin Ltd until it was sold to Ipsen, and was the Chair of Cancer Research Technology and a Trustee and Deputy-Chair of Cancer Research UK. During her career Melanie has held a number of positions at Glaxo, GlaxoWellcome, Celltech and UCB. In 2008, Melanie was honoured with a CBE for her services to Medical Science.
Chief Development Officer
Jamie Heath joined BTG in 2018 as Chief Development Officer, leading the development of BTG’s overall corporate strategy, including M&A plans, growth opportunities and digital activities.
Prior to joining BTG, Jamie was a Managing Director with Deutsche Bank where he represented select medtech, medical device and pharma companies. His career spans over 20 years in investment banking, providing strategic and financial advisory services to clients globally.
Chief Commercial Officer
John Sylvester joined BTG in January 2011, following the acquisition of Biocompatibles. John joined Biocompatibles in 2005 and was appointed to the Board in the same year.
His career covers a series of commercial roles for Rio Tinto Zinc plc, ICI plc and English China Clays where he was General Manager for their European and Asian Operations. Previously he was with Baxter Healthcare where he was VP Marketing for their European Medication delivery business.
Head of Interventional Oncology
Peter Pattison became head of BTG's Interventional Oncology business in January 2018. He joined BTG in July 2013 following the acquisition of TheraSphere from Nordion Inc.
At Nordion, Peter held a series of senior commercial roles, most recently Vice President of Sales, Marketing and Business Development for the company’s Targeted Therapies division that included TheraSphere. Prior to working at Nordion, Peter served as General Manager for the Asian/American Discovery Pharmacology business unit at MDS Pharma Services, a global Contract Research Organization. Peter started his career at Roche in Switzerland.
Head of Manufacturing & Supply
Head of Pharmaceuticals & US Commercial Operations
Anthony Higham joined BTG in January 2011 with responsibility for leading the global Manufacturing and Supply organisation; today in addition to these responsibilities Anthony also heads our Pharmaceutical business.
He has previously held a number of international and senior Operational and Technical roles at SmithKline Beecham, GlaxoSmithKline and Aesica Pharmaceuticals. Anthony has a BSc in Biological Sciences, BEng and MSc in Manufacturing Systems Engineering and a MSt awarded by the Institute of Manufacturing, Cambridge University.
Head of Human Resources
Yvonne Rogers joined BTG in December 2008 following the merger of BTG and Protherics. She joined Protherics in November 2003 to build Protherics’ Human Resources and Learning and Development activities across the global company.
Before joining Protherics she held senior roles at Troika UK Limited, KPMG, The Mitsubishi Bank and House of Fraser. A graduate of the Chartered Institute of Personnel and Development, she has spent over 20 years as a generalist Human Resources professional.
General Counsel, Head of Strategic Affairs
Head of PnuemRx
Joining BTG in 2000, Paul has over 20 years’ experience working with companies in the healthcare industry at all stages of development. He is Group General Counsel, Head of Strategic Affairs & Company Secretary.
As a member of the executive Leadership Team Paul is accountable for the Legal, Intellectual Property, Market Access and Healthcare Compliance functions. He is also responsible for management oversight of the PneumRx business. He has extensive experience of supporting the establishment of corporate governance & risk management frameworks; Corporate Finance; Mergers & Acquisitions (private & public); fundraisings and investment (equity, private equity & debt); IP licensing & business development; supporting drug and medical device research, development, manufacturing & commercialization; complex litigation and dispute resolution.
Paul has a BSc(Hons) in Biotechnology and a Ph.D in molecular biology and microbial physiology. Having qualified as a solicitor with Norton Rose Fulbright before joining BTG, Paul focused for a number of years in the area of corporate finance and corporate development before moving to the Equity Markets Group of the London Stock Exchange focusing on healthcare company transactions.
Paul is also a non-executive director and trustee of the charity LifeArc Limited, a business focused on the translation of R&D innovation into commercial products to better human health.
Head of Strategy
Paul McCubbin, MA, D Phil, ACA, joined BTG in 2001, working initially in the Corporate Venturing team and became head of that business unit in 2004. Since then he has taken on a succession of operational roles at BTG. In 2009 he was appointed General Manager of Varithena®, and became the Head of Varithena® in April 2013, following submission of a new drug application for the product in the US.
Prior to joining BTG, Paul was the Finance Director of Profiad Limited, a CRO spun-out of GlaxoWellcome. Previously, he led the corporate finance team in Ernst & Young’s life sciences group, advising early stage companies on strategy, partnering and fundraising. Paul qualified as a chartered accountant in 1995, whilst working in the corporate recovery and turnaround divisions at Arthur Andersen. Paul gained his degree and doctorate in biological sciences from the University of Oxford and worked as an MRC post-doctoral research fellow at Manchester University.
Head of Innovation
Peter Stratford joined BTG in January 2011, following the acquisition of Biocompatibles. Peter joined Biocompatibles in 1990 and was appointed to the Board in 2002. He took the role of Group Director Research and Development in 1998 and transitioned the Group to the current oncology products focus.
He joined the Cardiovascular Division Management Team at its creation in 1993, after completion of development work in contact lens application. Peter has a BSc in Chemistry, an MSc in Polymer Synthesis and a PhD in Pharmaceutical Synthesis.
We have a rich heritage. Learn about our transformation from commercialisation of intellectual property to medical technology used in minimally invasive procedures.Read more
Our Code of Conduct has been developed to promote ethical behaviour from all our employees and is based on our foundation of core company values.Read more